ArticleRespiration; international review of thoracic diseases2023
Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study.
Article in Respiration; international review of thoracic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- The role of 6-minute walk test and pulmonary function testing in patients with post COVID-19 condition: a systematic review and meta-analysis.Family practice · 2026Pooled it
- Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network.Frontiers in cellular and infection microbiology · 2023Pooled it
- Impact of COVID-19 on Subsequent Lung Function in Childhood: A Systematized Review.Health science reports · 2026Review
- Assessment of the Abnormalities in Chest Computed Tomography and Pulmonary Function Test in Convalescents Six Months After COVID-19.Medicina (Kaunas, Lithuania) · 2025Article
- A comparison of pulmonary function pre and post mild SARS-CoV-2 infection among healthy adults.BMC pulmonary medicine · 2025Observational
- Post-viral lung diseases: the microbiota as a key player.ERJ open research · 2025Review
- Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: a cross-sectional study.Scientific reports · 2024Article
- Persistent pulmonary impairment after 2 years of COVID-19 infection: An observational study.Lung India : official organ of Indian Chest Society · 2024Article
- Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- Proteomic Evolution from Acute to Post-COVID-19 Conditions.Journal of proteome research · 2024Article
- Review
- Residual Lung Abnormalities in Survivors of Severe or Critical COVID-19 at One-Year Follow-Up Computed Tomography: A Narrative Review Comparing the European and East Asian Experiences.Tomography (Ann Arbor, Mich.) · 2023Review
- Circulating calprotectin levels four months after severe and non-severe COVID-19.BMC infectious diseases · 2023Observational
- The long-term impact of COVID-19 pneumonia on pulmonary function and exercise capacity.Journal of thoracic disease · 2023Article
- Exosomal miR-17-5p, miR-146a-3p, and miR-223-3p Correlate with Radiologic Sequelae in Survivors of COVID-19-Related Acute Respiratory Distress Syndrome.International journal of molecular sciences · 2023Article
- Pulmonary Rehabilitation Outcomes of Post-Acute COVID-19 Patients during Different Waves of the Pandemic.International journal of environmental research and public health · 2023Article
- Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: a nationwide population-based cohort study.Frontiers in public health · 2023Article
- Changes on computed tomography in post-acute COVID-19 syndrome: systematic review and meta-analysis.Radiologia brasileiraReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung function impairment persists in some patients for months after acute coronavirus disease 2019 (COVID-19). Long-term lung function, radiological features, and their association remain to be clarified.
objectivesWe aimed to prospectively investigate lung function and radiological abnormalities over 12 months after severe and non-severe COVID-19.
methods584 patients were included in the Swiss COVID-19 lung study. We assessed lung function at 3, 6, and 12 months after acute COVID-19 and compared chest computed tomography (CT) imaging to lung functional abnormalities.
resultsAt 12 months, diffusion capacity for carbon monoxide (DLCOcorr) was lower after severe COVID-19 compared to non-severe COVID-19 (74.9% vs. 85.2% predicted, p < 0.001). Similarly, minimal oxygen saturation on 6-min walk test and total lung capacity were lower after severe COVID-19 (89.6% vs. 92.2%, p = 0.004, respectively, 88.2% vs. 95.1% predicted, p = 0.011). The difference for forced vital capacity (91.6% vs. 96.3% predicted, p = 0.082) was not statistically significant. Between 3 and 12 months, lung function improved in both groups and differences in DLCO between non-severe and severe COVID-19 patients decreased. In patients with chest CT scans at 12 months, we observed a correlation between radiological abnormalities and reduced lung function. While the overall extent of radiological abnormalities diminished over time, the frequency of mosaic attenuation and curvilinear patterns increased.
conclusionsIn this prospective cohort study, patients who had severe COVID-19 had diminished lung function over the first year compared to those after non-severe COVID-19, albeit with a greater extent of recovery in the severe disease group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.